Introduction
Malignant gliomas account for approximately 70% of all new cases of malignant primary brain tumors diagnosed in the United States every year. Glioblastoma Multiforme (GBM)
is the most common type of glioma, accounting for approximately 60 to 70% of malignant gliomas (CBTRUS, 2008; Wen and Kesari, 2008) and claiming 12,000 lives every year (Davis et al., 2001) . Epidermal growth factor receptor (EGFR) and its variant EGFRvIII play a critical role in the development of an aggressive phenotype of GBM; EGFR amplification, mutation and overexpression are associated with poor prognosis and resistance to therapy (Brandes et al., 2008) . Several therapeutic strategies targeting EGFR in GBM have been proposed, including the use of monoclonal antibodies against EGFR or EGFRvIII, vaccine therapies, bispecific antibodies, toxin-linked conjugates and small molecule tyrosine kinase inhibitors (Omuro et al., 2007) .
In recent years, several small molecule inhibitors targeting the tyrosine kinase EGFR have been introduced in clinical practice. Gefitinib (Iressa, ZD1839, AstraZeneca Pharmaceuticals) is an orally active compound that is a reversible inhibitor of the tyrosine kinase activity associated with EGFR, blocking EGFR signal transduction pathways (Arteaga and Johnson, 2001; Ciardiello and Tortora, 2001; Culy and Faulds, 2002) .
Despite equivocal results in phase III clinical trials (Giaccone et al., 2004; Herbst et al., 2004) , gefitinib was the first drug of its kind to be approved by the United States Food and Drug Administration for monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regimen.
However, results from studies evaluating the use of gefitinib for treatment in GBM have been disappointing. In phase II trials of gefitinib, patients with recurrent or progressive high-grade glioma showed no objective response, with a progression-free survival at 6months of 13 to 14% (Rich et al., 2004; Franceschi et al., 2007) . Similarly, no improvement in overall survival was observed in GBM patients at first relapse.
Studies explaining the failure of gefitinib have suggested that the reasons for this lack of efficacy could be related to the heterogeneous molecular characteristics of individual gliomas (Mellinghoff et al., 2005; Mellinghoff et al., 2007; Sarkaria et al., 2007) or due This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on April 26, 2010 as DOI: 10.1124 at ASPET Journals on April 29, 2016 jpet.aspetjournals.org Downloaded from J P E T # 1 6 7 6 0 1 5 to the complexity of signaling pathways such as negative feedback mechanisms and up regulation of alternative pathways (Stommel et al., 2007) . However, all of these hypotheses are based on the a priori assumption that there is adequate delivery of drug to the invasive tumor cells that can be found several centimeters away from the core tumor mass (Kuratsu et al., 1989; Silbergeld and Chicoine, 1997) . It is well known that ATPbinding cassette (ABC) transporter proteins, including p-glycoprotein (P-gp/ABCB1) and the breast cancer resistance protein (BCRP/ABCG2), cause multidrug resistance in tumors and actively extrude targeted therapeutics from the brain (Gottesman et al., 2002; Loscher and Potschka, 2005; Fletcher et al., 2010) . Certainly, the lack of gefitinib delivery to the invasive tumor cells residing in the CNS behind an intact blood-brain barrier (BBB) is a plausible partial explanation for the lack of efficacy seen in GBM.
There have been no published reports that indicate that transport of gefitinib across the intact BBB to the brain is limited. Several groups have studied the interaction of gefitinib with drug transport proteins in vitro and reported contrasting results. Elkind et al. reported in 2005 that BCRP actively pumps gefitinib and prevents its tyrosine kinase inhibitor activity (Elkind et al., 2005) . However shortly thereafter, Leggas et al. reported that gefitinib at clinically relevant concentrations is a potent inhibitor of BCRP and P-gp (Leggas et al., 2006) . Given the lack of evidence to prove that gefitinib can cross the BBB to produce therapeutic concentrations in the brain, it is important to study the brain distribution kinetics of gefitinib, and the mechanisms that may influence adequate delivery of gefitinib to the target invasive tumor cells. Here we have used in vitro cell models to demonstrate that gefitinib is a substrate for the ATP transporters P-gp and BCRP. We have also used transporter deficient mice to study the brain distribution of gefitinib. The objective of this study was to establish the interaction of gefitinib with two important transporters of the ABC super family, P-gp and BCRP, and to show that distribution of gefitinib across an intact BBB is limited due to active efflux by these two transport proteins.
Methods

Chemicals and Reagents
This article has not been copyedited and formatted. The final version may differ from this version. 
Intracellular Accumulation Studies in MDCKII Cells
The accumulation studies were done in 24-well polystyrene plates (Thermo Fisher Scientific, Rochester, NY). The wild-type and MDR1 or Bcrp1 transfected cells were seeded at a density of 2 × 10 5 cells/well. The medium was changed on alternate days until the cells formed confluent monolayers. On the day of the experiment, the medium was aspirated and the monolayer was washed twice with 1 mL prewarmed (37°C) assay (Dantzig et al., 1999; Allen et al., 2002) ) during both the preincubation and accumulation periods. The stock solutions for all the inhibitors used were prepared in dimethyl sulfoxide (DMSO) and diluted using assay buffer to obtain working solutions, so that the final concentration of DMSO was less than 0.1%.
Directional Flux across MDCKII Monolayers
Six-well transwells (Corning Inc., Corning, NY) were used in the permeability studies.
Cells were seeded at a density of 2 × 10 5 cells/well on the polyester semipermeable membrane supports and the medium was changed on alternate days until the cells formed confluent monolayers. On the day of experiment, the monolayers were washed with 2 mL prewarmed (37°C) assay buffer. After a 30-min preincubation period, the experiment was initiated by adding a tracer solution of radiolabeled drug ( 14 C-gefitinib) in assay buffer to the donor side (apical side, 1.5 ml; basolateral side, 2.6 ml). Fresh assay buffer was added to the receiver side and 200 μ l was sampled from the receiver compartment at 0, 10, 20, This article has not been copyedited and formatted. The final version may differ from this version. where dQ/dt is the mass transport rate (determined from the slope of the amount transported vs. time plot), A is the apparent surface area of the cell monolayer (4.67 cm 2 ), and C 0 is the initial donor concentration. The efflux ratio was defined as the ratio of P app in the B-to-A direction to the P app in the A-to-B direction and gives an indication of the magnitude of P-gp or BCRP-mediated efflux. The corrected flux ratio (CFR) was determined by dividing the efflux ratio in the Bcrp1 or MDR1 transfected cells by the efflux ratio in the corresponding wild-type cells.
In vivo studies
Animals
All animals used in this study were from Taconic Farms, Inc. (Germantown, NY). 
Brain Distribution of Gefitinib in FVB Mice
The dose formulation of gefitinib was prepared on the day of experiment at a concentration of 5 mg/ml. Gefitinib was suspended in 1% polysorbate 80 solution in saline or in a vehicle consisting of 10% DMSO, 35% propylene glycol, 5% ethanol and 50% saline. All mice received a 25 mg/kg oral dose of gefitinib via oral gavage.
In the first study, wild-type and Mdr1a/b -/-Bcrp1 -/mice were administered an oral dose of gefitinib (1% polysorbate 80) following which blood and brain were sampled at 15, 30, 60, 90, 120 and 240 minutes post-dose, n=4 at each time point. At the desired time point, animals were euthanized using a CO 2 chamber. Blood was collected by cardiac puncture and transferred to heparinized tubes. Plasma was isolated from blood by centrifugation at 3000 rpm for 10 min at 4
• C. Whole brain was immediately removed from the skull, rinsed with cold saline and flash frozen in liquid nitrogen. Plasma and brain specimens were stored at -80 • C until analysis by LC-MS/MS.
In another study, wild-type mice received an oral dose of gefitinib (10% DMSO, 35% propylene glycol, 5% ethanol and 50% saline) with or without an intravenous dose of 10 mg/kg elacridar (GF120918) 30 minutes prior to administration of gefitinib. Blood and brain were sampled at 15, 30, 60, 90 and 120 minutes post-dose as described above (n=4 at each time point). Gefitinib brain distribution was also studied after oral administration in a group of wild-type, Mdr1a/b -/-, Bcrp1 -/and Mdr1a/b -/-Bcrp1 -/mice and in wild-type mice which received 25 mg/kg LY335979 (20% ethanol, 80% saline), 10 mg/kg Ko143 (20% DMSO, 80% saline) or 10 mg/kg GF120918 (40% propylene glycol, 30% DMSO and 30% saline) intravenously 30 minutes before an oral gefitinib dose. Blood and brain were sampled at 90 minutes post-dose, n=4 at each time point. Alzet osmotic mini pumps (Durect Corporation, Cupertino, CA ) were used to study the steady state brain and plasma levels of gefitinib. A 70 mg/ml solution of gefitinib in DMSO was filled in the minipumps (model 1003D) and the pumps were equilibrated by soaking them overnight in sterile saline solution at 37 º C. The pump operated at a flow rate of 1 µL/hr yielding an infusion rate of 70 µg/hr. Wild-type and Mdr1a/b -/-Bcrp1 -/mice were anesthetized by intraperitoneal administration of 100 mg/kg ketamine and 10 mg/kg xylazine (Boynton Health Service Pharmacy, Minneapolis, MN). The abdominal cavity was shaved and cleaned. Next, a small midline incision was made in the lower abdomen under the rib cage. A small incision was then made in the peritoneal wall directly beneath the cutaneous incision and the primed pump was inserted into the peritoneal cavity. The musculoperitoneal layer was closed with sterile absorbable sutures and the skin incision was closed using sterile wound clips. The animals were allowed to recover on a heated pad. Gefitinib half-life in mice has been reported to be approximately 1 hour (Wang et al., 2008) , so an infusion lasting 24 hours was considered to be sufficient to attain steady-state in both brain and plasma. The animals were euthanized 24 and 48 hours post surgery followed by collection of brain and blood as described earlier.
Steady State Brain Distribution of Gefitinib
Determination of Gefitinib Concentrations in Plasma and Brain by LC-MS/MS
Prior to analysis, frozen samples were thawed at ambient temperature. Brain samples were homogenized using 3 volumes of 5% bovine serum albumin in phosphate-buffered saline using a tissue homogenizer (Fisher Scientific, Pittsburgh, PA). A 50 µL aliquot of plasma and a 100 µL aliquot of brain homogenate were used for analysis. Plasma and brain samples were spiked with 10 ng of dasatinib (IS) as internal standard followed by Fisher Scientific Co., Pittsburgh, PA) was added to 100 µL of brain or 20 µL plasma specimens and counted using liquid scintillation counting (LS-6500; Beckman Coulter Inc., Fullerton, CA) to determine the radioactivity associated with sucrose and inulin in the samples. Sucrose and inulin concentrations in brain and plasma were determined.
Brain space was calculated as the ratio of the brain concentration (nCi/gm) to the plasma concentration (nCi/ml) and expressed as the percentage of brain volume (µL) exposed to the two compounds.
Statistical Analysis
Statistical analysis was conducted using SigmaStat, version 3.1 (Systat Software, Inc., Point Richmond, CA). Statistical comparisons between two groups were made by using two-sample t-test at p < 0.05 significance level. Multiple groups were compared by one way analysis of variance with the Holm-Sidak post-hoc test for multiple comparisons at a significance level of p < 0.05.
Results
Intracellular Accumulation of Gefitinib
Accumulation of gefitinib in MDCKII wild-type ( Figure 1B) .
Accumulation of gefitinib in the Bcrp1-transfected cells was significantly lower than that in the wild-type cells (~ 3% of WT control, p<0.001). This difference in accumulation between the two cell types was abolished upon treatment with the BCRP specific inhibitor Ko143 (200 nM) ( Figure 1A) . In the MDR1-transfected cells, accumulation of gefitinib was 50% lower than that in the wild-type cells (p<0.001). Treatment with the Pgp inhibitor LY335979 (1µM) decreased the difference in accumulation ( Figure 1B) . 4 (Figure 2B ). The P-gp inhibitor LY335979 reversed the directionality in flux due to P-gp, such that there was no significant difference in the permeability of gefitinib in both directions, and the efflux ratio decreased to 1. Again, the B-to-A and A-to-B permeability was similar in the corresponding wild-type cells. The corrected efflux ratio was approximately 5.1 in the control and 0.9 in the cells treated with LY335979.
Directional Permeabilites of Gefitinib across MDCKII Monolayers
Brain Distribution of Gefitinib in Wild-type and Mdr1a/b -/-Bcrp1 -/mice
We investigated the effect of p-glycoprotein and BCRP on the brain distribution of gefitinib using wild-type and transgenic mouse models. Brain distribution after a 25 mg/kg oral dose of gefitinib was determined in FVB wild-type and Mdr1a/b -/-Bcrp1 -/mice. Brain concentrations of gefitinib were significantly lower than the plasma concentrations in the wild-type mice (p<0.05), resulting in a brain-to-plasma (B/P) concentration ratio of less than 0.15 at all measured time points (Figure 3) . However, gefitinib brain concentrations were significantly enhanced in the Mdr1a/b -/-Bcrp1 -/mice compared to those in the wild-type mice (p<0.05, Figure 4A) . The brain-to-plasma concentration ratio was significantly greater in the Mdr1a/b -/-Bcrp1 -/mice at all the measured time points (p<0.001). The B/P ratio was on average 16-fold higher in the Mdr1a/b -/-Bcrp1 -/mice compared to the wild-type mice ( Figure 4B) . Plasma concentrations of gefitinib in the Mdr1a/b -/-Bcrp1 -/mice were not significantly different compared to the plasma concentrations in the wild-type mice. We investigated if pharmacological inhibition of P-gp and BCRP at the blood-brain barrier enhances the brain exposure of gefitinib in FVB wild-type mice. The dual P-gp and BCRP inhibitor elacridar (GF120918) was used for this purpose. Brain gefitinib concentrations were greater in the elacridar treated group compared to control ( Figure   5A ). The brain-to-plasma concentration ratio (B/P) was significantly greater in the elacridar treated wild-type mice compared to the control (p<0.05; Figure 5B) . The brainto-plasma ratio increased by more than 4-fold when elacridar was administered along with gefitinib, reaching values greater than 1 at the later time points. This indicates that brain distribution of gefitinib can be significantly improved by concurrent administration of a dual inhibitor like elacridar.
Dual P-gp and BCRP Inhibitor Elacridar Enhances Brain Distribution of Gefitinib
Effect of Pharmacological Inhibition and Genetic Deletion of P-gp and BCRP
We studied the brain distribution of gefitinib in wild-type, Mdr1a/b -/-, Bcrp1 -/and Mdr1a/b -/-Bcrp1 -/mice and in wild-type mice that were pretreated with pharmacological inhibitors of P-gp (LY335979), BCRP (Ko143) and the dual P-gp/BCRP inhibitor elacridar. Figure 6 shows the brain-to-plasma ratios of gefitinib when P-gp and BCRP were pharmacologically inhibited or genetically deleted. Use of LY335979 and Ko143 did not result in any significant change in the B/P ratio of gefitinib, however the B/P ratio increased by ~6-fold in the wild-type mice that were pretreated with the dual inhibitor elacridar (p<0.05). Similarly, in the gene knockout group, the B/P ratio increased by approximately 4-fold in the Mdr1a/b -/mice (p<0.05). While there was no change in the B/P ratio in the Bcrp1 -/mice, the ratio increased by greater than 18-fold in the Mdr1a/b -/-Bcrp1 -/mice (p<0.001). Table 1 summarizes the results from steady state brain and plasma distribution of gefitinib after a continuous intraperitoneal infusion. In the wild-type mice, steady-state brain concentrations of gefitinib were 15-fold lower than the corresponding plasma concentrations (p<0.001). The brain-to-plasma ratio was approximately 0.1 at both the measured time points, indicating a brain tissue partition coefficient of 10% in the wildtype mice. In the Mdr1a/b -/-Bcrp1 -/mice, brain concentrations were ~ 7-fold greater compared to the plasma concentrations (p<0.001). Steady state brain concentrations in the Mdr1a/b -/-Bcrp1 -/mice increased more than 50-fold compared to that in the wildtype mice (p<0.001). The corresponding brain-to-plasma ratios in the Mdr1a/b -/-Bcrp1 -/mice were about 7, indicating a 70-fold increase in brain partitioning of gefitinib compared to the wild-type. There was no difference in the brain-to-plasma ratios between the 24 hr and the 48 hr time points in the two mice groups.
Steady-State Brain Distribution of Gefitinib
Blood-Brain Barrier Integrity in FVB Mdr1a/b -/-Bcrp1 -/mice
The integrity of the BBB in the Mdr1a/b -/-Bcrp1 -/mice was evaluated to ensure that the dramatic increase in brain distribution of gefitinib observed in the triple knockout mice was not a result of a leaky blood-brain barrier (compromised tight junctions). This was done by determining the brain spaces of Figure 7) . The finding confirmed that there was no change in the integrity of the tight junctions that form the BBB in the Mdr1a/b -/-Bcrp1 -/mice. This suggests that the cumulative change in brain distribution of gefitinib in these mice is due to the simultaneous absence of both drug efflux systems.
Discussion
The epidermal growth factor receptor (EGFR) pathway has been an attractive target because it is dysregulated in a significant fraction of malignant gliomas through overexpression, amplification and activating mutations (Rich et al., 2004) . Moreover, recent studies have demonstrated that EGFRvIII is required for tumor maintainence in glioma (Mukasa et al., 2010) . The EGFR tyrosine kinase inhibitor gefitinib has been evaluated in a number of clinical trials for GBM, however results have been disappointing (Lieberman FS, 2004; Rich et al., 2004) . The failure of gefitinib raises questions pertaining to delivery of drug to its target. Active efflux at the BBB could prevent drugs from attaining therapeutic levels in the brain and is likely one of the main reasons behind resistance to chemotherapy. It has been shown that several other tyrosine kinase inhibitors are avid substrates for P-gp and BCRP and that their brain distribution is limited due to active efflux out of the brain (Dai et al., 2003; Chen et al., 2009; Lagas et al., 2009; Polli et al., 2009) . Whether gefitinib crosses the BBB to achieve therapeutic levels in the CNS is an important question that has remained unanswered. We have raised this question herein and demonstrated that gefitinib is a substrate of the ABC transporters P-gp and BCRP and that these two efflux proteins actively efflux gefitinib at the BBB, thereby limiting its brain penetration. We have further demonstrated that steady-state brain partitioning improved by greater than 70-fold due to absence of both P-gp and BCRP in the Mdr1a/b -/-Bcrp1 -/mice and that inhibition of these two transporters by use of a dual inhibitor like elacridar can be a useful therapeutic strategy to improve brain distribution of gefitinib.
In vitro studies conducted in immortalized MDCKII cells that stably overexpress human P-gp or murine BCRP demonstrated that gefitinib is a substrate of the two efflux pumps.
It has been reported that gefitinib is an inhibitor of P-gp and BCRP and that concurrent administration increases the bioavailability of topotecan (Leggas et al., 2006) . Our study conclusively shows that gefitinib is a substrate for these two transporters. One explanation for the inhibitory effect seen could be given by the high gefitinib concentrations used by Leggas et al. in the above mentioned study. It is also possible that gefitinib competes with other substrates to bind with P-gp and BCRP and saturates the transporters thus leading to their inhibition.
In vivo studies using FVB wild-type mice showed that CNS distribution of gefitinib across the blood-brain barrier is significantly limited. Brain concentrations were on average 18-fold higher in the Mdr1a/b -/-Bcrp1 -/mice than in the wild-type mice. Steadystate brain-to-plasma ratios increased from ~ 0.1 in the wild-type mice to ~ 7 in the Mdr1a/b -/-Bcrp1 -/mice. This dramatic 70-fold increase in the brain partitioning indicates the significant impact the two transporters have on the brain distribution of gefitinib. The dramatic increase in brain gefitinib concentrations in the Mdr1a/b -/-Bcrp1 -/mice suggested that inhibition of P-gp and BCRP might be an effective way to improve brain distribution of gefitinib. Therefore, we studied the influence of the dual P-gp and BCRP inhibitor elacridar on the brain distribution of gefitinib in FVB wild-type mice. Treatment with elacridar resulted in enhanced brain levels of gefitinib in the wild-type mice. This finding demonstrates the improvement in delivery of gefitinib to the brain resulting from pharmacological inhibition of active efflux at the BBB. Interestingly, plasma concentrations of gefitinib were not increased in the Mdr1a/b -/-Bcrp1 -/mice or in the elacridar-treated wild-type mice compared to control wild-type mice, suggesting that under these experimental conditions P-gp and BCRP do not limit oral uptake of gefitinib.
This finding is in agreement with other studies which report that oral absorption of TKIs like dasatinib and erlotinib is not influenced by P-gp and BCRP (Kamath et al., 2008; Lagas et al., 2010) .
In the study to determine the relative contribution of P-gp and BCRP in active efflux of gefitinib, pharmacological inhibition of BCRP by Ko143 or genetic deletion in Bcrp1 -/mice did not result in any significant increase in brain levels of gefitinib. Brain concentrations and the brain-to-plasma ratios increased by greater than 3-fold when P-gp was absent in the Mdr1a/b -/mice. More importantly, concomitant inhibition of P-gp and BCRP by elacridar resulted in a ~ 6-fold increase in the brain-to-plasma ratio while absence of both transporters in the Mdr1a/b -/-Bcrp1 -/mice had an even greater effect with the B/P ratio increasing by greater than 18-fold. This indicates that P-gp seems to be the dominant transporter when it comes to efflux of gefitinib from the brain. However, the fact that brain concentrations increase only marginally when P-gp is inhibited or absent, suggests that BCRP efflux may compensate for the loss of P-gp. This is highlighted in the Mdr1a/b -/-Bcrp1 -/mice or by the use of elacridar which resulted in a greater than additive increase in brain gefitinib levels. This is consistent with previous reports for dasatinib (Chen et al., 2009; Lagas et al., 2009 ) and other published reports for tyrosine kinase inhibitors, including imatinib and lapatinib (Oostendorp et al., 2009; Polli et al., 2009) . The in vivo finding that BCRP by itself does not influence brain penetration of gefitinib is in agreement with reports for other TKIs. One explanation for this could be the presence of significantly low levels of BCRP in the rodent and human BBB compared account for the discrepancies between the in vitro cell and the in vivo models (Lee et al., 2007) . It is also possible that there are differences in the capacities of the two transporters at the BBB where P-gp might seem to play a predominant role at the BBB.
Previous studies have reported similar findings where the brain concentrations of dual Pgp/BCRP substrates increased dramatically in the Mdr1a/b -/-Bcrp1 -/mice (Polli et al., 2009 ). This raised questions about the validity of the triple knockout mice as a model system to study drug transport to the CNS. Some of these questions pertain to the integrity of the BBB in these mice. We decided to evaluate this by studying the brain distribution of sucrose and inulin. Sucrose and inulin do not readily cross membranes and under normal conditions, shortly after systemic dosing, do not enter the brain to any significant extent. A leakier BBB in the Mdr1a/b -/-Bcrp1 -/mice would result in higher brain levels of these two compounds compared to the wild-type mice. We observed no differences in the brain concentrations of [ 14 C] sucrose and [ 14 C] inulin between the wildtype and Mdr1a/b -/-Bcrp1 -/mice. The brain space was ~2 % for sucrose and inulin in both wild-type and the Mdr1a/b -/-Bcrp1 -/mice. This confirmed that these mice have an intact blood-brain barrier and therefore the dramatically high brain concentrations of substrate drugs in these mice are most probably due to the simultaneous absence of P-gp and BCRP at the BBB, that would not allow for compensatory transport when one or the other is present.
Limited CNS distribution of gefitinib due to active efflux transport at the BBB can be of significance while trying to elucidate the reasons behind the lack of gefitinib efficacy seen in brain tumors like GBM. It has been suggested that delivery of gefitinib across the BBB might not be an issue in GBM since tumor concentrations 10-to 12-fold higher than plasma concentrations have been reported (McKillop et al., 2005; Hofer and Frei, 2007) .
One explanation for this increased tumor penetration of gefitinib can be given by the breakdown of the BBB at the contrast-enhancing tumor core. Also, while the BBB may be disrupted at or near the core, there is increasing evidence to show that it is still intact near the growing edge of the infiltrative tumor (Fine et al., 2006; Blakeley et al., 2009) , the site where invasive tumor initiating cells reside. Tumor recurrence after surgical removal and radio-chemotherapy questions the delivery of drug to the non-tumor containing areas of brain that may only have limited access to the drug. Brain tumor initiating cells residing behind an intact BBB can pose significant delivery problems and might be one of the main reasons behind the recurrence of tumor after surgery. Despite recent advances in therapy, malignant glioma remains essentially fatal, with a median survival of 10-12 months. There are no studies that examine the failure of gefitinib chemotherapy in GBM that address the lack of drug delivery to the intended molecular target in tumor-initiating cells that reside behind an intact BBB. This lack of adequate delivery may be an important reason for the ineffectiveness of gefitinib in brain tumors like GBM.
In conclusion, we have shown here that the ATP transporters P-gp and BCRP actively efflux gefitinib at the blood-brain barrier and limit its CNS distribution. We have highlighted that gefitinib is another example where P-gp and BCRP can work together to dramatically limit brain distribution of dual substrates. We have also shown that the tight junctions that form the BBB are intact in the Mdr1a/b -/-Bcrp1 -/mice and that the enhanced CNS distribution seen in these mice is due to the absence of P-gp and BCRP.
Finally, coadministration of the dual P-gp/BCRP inhibitor elacridar was able to significantly enhance brain distribution of gefitinib. This can be of importance in therapy for GBM, where limited distribution to the target tumor cells, i.e., the invasive glioma cells behind an intact blood-brain barrier, might be one of the reasons behind the lack of efficacy seen with gefitinib. Treatment with LY335979 reduced the difference in accumulation between the two cell types. Results presented as mean ± SE, n = 18. The brain spaces of sucrose or inulin in the Mdr1a/b -/-Bcrp1 -/mice were similar to that in the wild-type mice indicating that the BBB is intact in these mice. The values are presented as mean ± S.E (n = 4).
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